What is the primary purpose of this 10-K filing?

This 10-K filing is Eli Lilly and Company's annual report, providing a comprehensive overview of the company's financial performance, business operations, and risk factors for the fiscal year ending December 30, 1995. It is a key document for investors seeking detailed information about the company's health and strategic direction.

What kind of information should investors look for in this report, given the limited content provided?

Investors should look for information that would typically be included in a 10-K, such as details on revenue sources, significant product lines, research and development activities, competitive landscape, and management's discussion and analysis of financial condition and results of operations. Understanding these aspects helps in assessing the company's long-term viability and growth potential.

What is the significance of the filing date (March 24, 1996)?

The filing date indicates that the report covers the company's performance for the entire fiscal year 1995 and was submitted to the SEC shortly after the year-end. This allows investors to have a timely update on the company's financial results and business status for the concluded year.

Where can I find the full content of this 10-K filing?

The provided text is a directory listing from the SEC's EDGAR database. To access the full 10-K report, you would typically need to navigate to the linked files within the EDGAR system, such as the .txt or .htm files that contain the complete report content.

LLY 10-K FY1995 Annual Report — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 1995 10-K filing reflects a company operating in the dynamic pharmaceutical sector. The filing provides a snapshot of the company's financial health and strategic direction as of December 30, 1995. While specific financial figures and operational details are not fully present in the provided directory listing, this report would typically detail revenue streams, product pipelines, research and development investments, and market positioning. Investors would look to this report to assess the company's ability to innovate and bring new drugs to market, manage its existing product portfolio, and navigate the competitive landscape of the pharmaceutical industry.

Key Highlights

1The filing is Eli Lilly and Company's Annual Report (10-K) for the period ending December 30, 1995, filed on March 24, 1996.
2This report provides essential financial and operational information for investors regarding LLY's performance.
3The filing offers insights into the company's product portfolio and its position within the pharmaceutical market as of that period.
4Investors can use this report to evaluate the company's growth prospects and strategic initiatives.
5Key areas of interest for investors would include research and development pipelines and market penetration strategies.
6The filing serves as a crucial document for understanding the company's financial standing and business operations in the mid-1990s.

ELI LILLY & Co Annual Report, Year Ended Dec 31, 1995

Summary

Key Highlights

Frequently Asked Questions